Suppr超能文献

嫌色细胞肾细胞癌:肿瘤分级对预后的影响。

Chromophobe renal cell carcinoma: the impact of tumor grade on outcome.

机构信息

Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

出版信息

Am J Surg Pathol. 2012 Jun;36(6):851-6. doi: 10.1097/PAS.0b013e3182496895.

Abstract

It has been reported that Fuhrman grading is not appropriate for chromophobe renal cell carcinoma (RCC). The objective of this study was to determine whether nucleolar grading and the recently described chromophobe RCC grading system by Paner and colleagues provide prognostic information. Pathologic features of 185 patients with chromophobe RCC treated surgically between 1970 and 2006 were reviewed, including nucleolar grade, chromophobe RCC grade, the 2010 TNM groupings, sarcomatoid differentiation, and coagulative tumor necrosis. Cancer-specific (CS) survival was estimated using the Kaplan-Meier method, and associations with CS survival were evaluated using Cox proportional hazard regression models. Twenty-three patients died from RCC at a mean of 3.0 years after surgery (median 1.3; range 0 to 16) with estimated CS rates (95% confidence interval) of 89% (84 to 94), 86% (81 to 92), and 85% (78 to 91) at 5, 10, and 15 years after surgery. Univariate associations with CS survival included the 2010 TNM stage groupings, sarcomatoid differentiation, coagulative tumor necrosis, chromophobe RCC grade, and nucleolar grade (all P<0.001). These last 4 features remained significantly associated with CS survival after adjusting for the 2010 TNM stage groupings. When the analysis was restricted to the 155 patients with nonsarcomatoid TNM stage groupings I and II chromophobe RCC, only stage grouping (I vs. II) was significantly associated with CS survival (P=0.03). Although the chromophobe RCC grading system described by Paner and colleagues and nucleolar grade are associated with CS survival in chromophobe RCC, they add no additional prognostic information once TNM stage and sarcomatoid differentiation are assessed.

摘要

据报道,Fuhrman 分级法不适用于嫌色细胞肾细胞癌(RCC)。本研究旨在确定核仁分级和 Paner 及其同事最近描述的嫌色细胞 RCC 分级系统是否提供预后信息。回顾了 1970 年至 2006 年间接受手术治疗的 185 例嫌色细胞 RCC 患者的病理特征,包括核仁分级、嫌色细胞 RCC 分级、2010 年 TNM 分组、肉瘤样分化和凝固性肿瘤坏死。采用 Kaplan-Meier 法估计癌症特异性(CS)生存率,并采用 Cox 比例风险回归模型评估 CS 生存率与各因素的相关性。23 例患者死于 RCC,术后平均 3.0 年(中位数 1.3;范围 0 至 16),术后 5、10 和 15 年 CS 率(95%置信区间)估计值分别为 89%(84 至 94)、86%(81 至 92)和 85%(78 至 91)。与 CS 生存率相关的单因素包括 2010 年 TNM 分期分组、肉瘤样分化、凝固性肿瘤坏死、嫌色细胞 RCC 分级和核仁分级(均 P<0.001)。调整 2010 年 TNM 分期分组后,这后 4 个特征与 CS 生存率仍显著相关。当分析仅限于 155 例无肉瘤样 TNM 分期 I 和 II 期的嫌色细胞 RCC 患者时,仅分期分组(I 期 vs. II 期)与 CS 生存率显著相关(P=0.03)。尽管 Paner 及其同事描述的嫌色细胞 RCC 分级系统和核仁分级与嫌色细胞 RCC 的 CS 生存率相关,但在评估 TNM 分期和肉瘤样分化后,它们并未提供额外的预后信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验